Overview

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Status:
Recruiting

Trial end date:
2029-09-20

Target enrollment:

Participant gender:

Summary

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Hoffmann-La Roche

Treatments:

Ado-Trastuzumab Emtansine
Atezolizumab
Docetaxel
Maytansine
Paclitaxel
Pertuzumab
Trastuzumab